A Phase 1 study of FL118 in advanced pancreatic cancer
Withdrawn Phase 1 NCT06206876
Study Description
A study evaluating a new drug called FL118 for treating advanced pancreatic cancer
Study Details
- Registry ID:
- NCT06206876
- Conditions:
- Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Phase:
- Phase 1
- Start Date:
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Roswell Park Cancer Institute
Buffalo, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.